Letrozol Medical Valley

Letrozole, the active ingredient in Letrozol Medical Valley, is an aromatase inhibitor presented as an oral formulation for oral use. It is employed in the treatment of hormone receptor‑positive breast cancer in postmenopausal women, where reducing estrogen synthesis helps control tumor growth.

GNH USA supplies Letrozol Medical Valley as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide. The company adheres to EU quality standards and provides reliable logistics for global distribution. Customers benefit from consistent batch release, regulatory support, and responsive technical assistance.

Letrozole is used in endocrine therapy targeting estrogen‑dependent breast cancer. - Adjuvant treatment of hormone receptor‑positive breast cancer in postmenopausal women: reduces risk of disease recurrence after surgery. - Metastatic hormone receptor‑positive breast cancer in postmenopausal women: slows disease progression and prolongs survival. - Neoadjuvant therapy for locally advanced hormone receptor‑positive breast cancer: facilitates tumor shrinkage before surgery.

Letrozole may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Hot flashes - Joint and muscle pain - Fatigue - Nausea - Headache - Insomnia

Serious or Rare Side Effects: - Severe osteoporosis or bone fractures - Venous thromboembolism (deep vein thrombosis, pulmonary embolism) - Liver function test abnormalities - Severe skin reactions such as Stevens‑Johnson syndrome - Interstitial lung disease or pneumonitis

When prescribing Letrozole, several safety considerations should be observed. - Assess bone health: obtain baseline DEXA scan and monitor bone density during therapy. - Monitor liver function: perform periodic liver enzyme tests. - Evaluate cardiovascular risk: review history of thromboembolic events before initiating. - Contraindicated in pregnancy: avoid use in pregnant women (Category X). - Use caution in severe renal impairment: adjust dosing or consider alternative therapy. - Store at ambient temperature below 25°C: keep in original packaging, protect from moisture.

Letrozole can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Concurrent estrogen replacement therapy: may diminish letrozole efficacy. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): can lower plasma concentrations. - Tamoxifen co‑administration: antagonistic effect on estrogen blockade.

Moderate Interactions (Monitor Closely): - Warfarin: letrozole may increase INR, require coagulation monitoring. - Selective serotonin reuptake inhibitors (e.g., fluoxetine): may affect metabolism, observe for side effects. - Antacids containing aluminum or magnesium: may reduce absorption, separate dosing by at least 2 hours.